How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

849 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management (PubMed)

Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management Agranulocytosis is a rare but serious complication of antithyroid drug therapy, and an up-to-date understanding of this topic is important. Both direct toxicity and immune-mediated responses have been described as possible mechanisms. Some major susceptibility loci have recently been identified, which may lead the diagnosis of agranulocytosis into a genomic era. Onset is acute and patients present (...) with symptoms and signs of infection together with high fever. Clinical suspicion is pivotal and should prompt blood sampling. An absolute neutrophil count of <500/μl in the presence of antithyroid drugs establishes the diagnosis. The causative drug should immediately be stopped to prevent further damage. Treatment includes broad-spectrum antibiotics and granulocyte-colony stimulation factor in selected patients. Later, patients will need definitive treatment for hyperthyroidism, usually with radioactive

Full Text available with Trip Pro

2017 Drugs in R&D

22. Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease (PubMed)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease Graves' disease (GD) accounts for a large proportion of pediatric hyperthyroidism, and the first-line treatment is antithyroid drug (ATD) therapy. Methimazole (MMI) is effective in most patients but is associated with significant adverse events (AEs). We reviewed the medical records of GD patients (n = 56) with onset age of <15 yr and investigated the relationship between MMI dose

Full Text available with Trip Pro

2017 Clinical Pediatric Endocrinology

23. Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China (PubMed)

Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China Antithyroid drug (ATD)-induced agranulocytosis is associated with human leukocyte antigen (HLA) and nearby genes in Southeast Asian and European populations. The susceptibility of the Han population from northern China to ATD-induced agranulocytosis has not been reported. We evaluated the associations of genetic variants at the HLA-B and HLA-DRB1 loci and 32

Full Text available with Trip Pro

2017 Scientific reports

24. Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease (PubMed)

Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves’ Disease Graves' disease (GD) is one of the most common endocrine diseases. Antithyroid drugs (ATDs) treatment is frequently used as the first-choice therapy for GD patients in most countries due to the superiority in safety and tolerance. However, GD patients treated with ATD have a relatively high recurrence rate after drug withdrawal, which is a main limitation for ATD

Full Text available with Trip Pro

2017 Frontiers in endocrinology

25. Erratum: antithyroid drug induced agranulocytosis: what still we need to learn? (PubMed)

Erratum: antithyroid drug induced agranulocytosis: what still we need to learn? [This corrects the article DOI: 10.11604/pamj.2016.23.27.8365.].

Full Text available with Trip Pro

2016 The Pan African medical journal

26. Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease (PubMed)

Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease Hyperthyroidism relapse in Graves disease after antithyroid drug (ATD) withdrawal is common; however, measuring the thyrotropin receptor antibody (TRAb) at ATD withdrawal in order to predict outcomes is controversial. This study compared measurement of thyroid stimulatory antibody (TSAb) and thyrotropin-binding inhibitory immunoglobulin (TBII) at ATD

Full Text available with Trip Pro

2016 Endocrinology and Metabolism

27. Antithyroid drug-associated MPO-ANCA-positive tubulointerstitial nephritis in a type 2 diabetes patient: a case report (PubMed)

Antithyroid drug-associated MPO-ANCA-positive tubulointerstitial nephritis in a type 2 diabetes patient: a case report A 54-year-old man diagnosed with type 2 diabetes and hyperthyroidism was prescribed propylthiouracil (PTU) after the patient developed hepatic dysfunction on thiamazole. At 50 mg/day of PTU, he was stable with thyroid-stimulating hormone receptor and thyrotropic antibody titers remaining stable. After four years of taking PTU, he was referred to the Department of Nephrology due

Full Text available with Trip Pro

2016 CEN Case Reports

28. The second antithyroid drug treatment is effective in relapsed Graves' patients: a median 11-year follow-up study. (PubMed)

The second antithyroid drug treatment is effective in relapsed Graves' patients: a median 11-year follow-up study. Antithyroid drug (ATD) is a widely used treatment for Graves' disease (GD). However, its long-term efficiency remains unclear. This study investigated the long-term disease prognosis and predictive factors for relapse in ATD-treated GD patients.Newly diagnosed, ATD-treated GD patients with at least four years of follow-up were recruited (n = 187). Remission was defined

2016 Thyroid

29. Cost-Utility Analysis Comparing Radioactive Iodine, Antithyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves' Disease. (PubMed)

Cost-Utility Analysis Comparing Radioactive Iodine, Antithyroid Drugs and Total Thyroidectomy for Primary Treatment of Graves' Disease. Little data is in existence about the most cost-effective primary treatment for Graves' disease. We performed a cost-utility analysis comparing radioactive iodine (RAI), anti-thyroid drugs (ATD) and total thyroidectomy (TT) as first-line therapy for Graves' disease in England and Australia.We used a Markov model to compare lifetime costs and benefits (quality

Full Text available with Trip Pro

2016 European Journal of Endocrinology

30. Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials. (PubMed)

Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials. This meta-analysis was performed to compare radioiodine therapy with antithyroid drugs in terms of clinical outcomes, including development or worsening of ophthalmopathy, hyperthyroid cure rate, hypothyroidism, relapse rate and adverse events.Randomized controlled trials (RCTs) published in PubMed, Embase, Web of Science, SinoMed and National Knowledge Infrastructure, China, were (...) systematically reviewed to compare the effects of radioiodine therapy with antithyroid drugs in patients with Graves' disease. Results were expressed as risk ratio with 95% confidence intervals (CIs) and weighted mean differences with 95% CIs. Pooled estimates were performed using a fixed-effects model or random-effects model, depending on the heterogeneity among studies.17 RCTs involving 4024 patients met the inclusion criteria and were included. Results showed that radioiodine treatment has increased risk

Full Text available with Trip Pro

2016 The British journal of radiology

31. The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation (PubMed)

The effect of prior antithyroid drug use on delaying remission in high uptake Graves' disease following radioiodine ablation Antithyroid drugs (ATDs) have been shown to attenuate the effectiveness of radioiodine (radioiodine ablation, RIA) therapy in Graves' disease. We undertook a study to look at the impact of iodine uptakes on the outcome of (131)I therapy. To determine the effect of prior ATD use on the duration of time to achieve cure in patients with high vs intermediate uptake Graves

Full Text available with Trip Pro

2016 Endocrine connections

32. Antithyroid Drug

Antithyroid Drug Antithyroid Drug Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Antithyroid Drug Antithyroid Drug Aka: Antithyroid (...) PTU dose down after 4-6 weeks Goal: maintain normal function Dose: reduce to 50-100 mg per day Dosing: Other : 1 gram load, then 300 mg PO q6 hours : 50-100 mg PO qd V. Adverse effects (3 per 1000 patients) (more common with PTU) Risk increases over age 40 years Occurs in 0.17% of those on Methimazole Presentation: Infection (e.g. ) Course Resolves within 2-3 weeks after drug stopped Severe, refractory course may occur Contraindication to further Antithyroid Drugs Cholestatic Occurs more commonly

2018 FP Notebook

33. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. (PubMed)

Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. Genotyping increases the accuracy of a clinical score (based on pretreatment age, goiter size, FT4, TBII) for predicting recurrence of Graves' hyperthyroidism after a course of antithyroid drugs: a prospective study.

Full Text available with Trip Pro

2016 Journal of Clinical Endocrinology and Metabolism

34. Antithyroid Drug Side Effects in the Population and in Pregnancy. (PubMed)

Antithyroid Drug Side Effects in the Population and in Pregnancy. Methimazole (MMI) and propylthiouracil (PTU) are both associated with birth defects and may also rarely be associated with agranulocytosis and liver failure. The frequency of these side effects when antithyroid drugs (ATDs) are used in the population in general or in pregnancy remains to be elucidated.All individuals registered as the parent of a live-born child in Denmark, 1973–2008, were identified (n = 2 299 952) and studied

Full Text available with Trip Pro

2016 Journal of Clinical Endocrinology and Metabolism

35. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. (PubMed)

Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: A retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Antithyroid drug (ATD)-induced agranulocytosis is a rare but life-threatening disease. Clinical features of ATD-induced agranulocytosis and outcomes remain incompletely understood.Patients with clinically diagnosed ATD-induced agranulocytosis were

2016 Thyroid

36. Predicting relapse of Graves' disease following treatment with antithyroid drugs (PubMed)

Predicting relapse of Graves' disease following treatment with antithyroid drugs The aim of the present study was to monitor long term antithyroid drug treatments and to identify prognostic factors for Graves' disease (GD). A total of 306 patients with GD who were referred to the Endocrinology Clinic at Weifang People's Hospital (Weifang, China) between August 2005 and June 2009 and treated with methimazole were included in the present study. Following treatment, patients were divided into non (...) and 12 months post-treatment. Patients with GD exhibiting large thyroids, high pre-mediation TRAb levels and elevated FT3/FT4 ratios responded less markedly to antithyroid drug treatments, as compared with patients not exhibiting these prognostic factors. Furthermore, patients with large thyroids, post-medication ophthalmopathy and continued thyrotropin suppression demonstrated higher rates of recurrence.

Full Text available with Trip Pro

2016 Experimental and therapeutic medicine

37. Antithyroid drug induced agranulocytosis: what still we need to learn ? (PubMed)

Antithyroid drug induced agranulocytosis: what still we need to learn ? Antithyroid drugs (ATDs) induced agranulocytosis is a rare but life threatening condition. We report a 29 years Filipino female diagnosed as having hyperthyroidism with normal base line blood counts, liver and renal profile. She was started on maximum 60 mg (20mg TID) oral dose of carbimazole since one month by her treating physician. Exactly after one month of treatment she presented to emergency room (ER) with fever, sore

Full Text available with Trip Pro

2016 The Pan African medical journal

38. Dual binding mode of antithyroid drug methimazole to mammalian heme peroxidases – structural determination of the lactoperoxidase–methimazole complex at 1.97 Å resolution (PubMed)

Dual binding mode of antithyroid drug methimazole to mammalian heme peroxidases – structural determination of the lactoperoxidase–methimazole complex at 1.97 Å resolution Lactoperoxidase (LPO, EC 1.11.1.7) is a member of the mammalian heme peroxidase family which also includes thyroid peroxidase (TPO). These two enzymes have a sequence homology of 76%. The structure of LPO is known but not that of TPO. In order to determine the mode of binding of antithyroid drugs to thyroid peroxidase, we (...) have determined the crystal structure of LPO complexed with an antithyroid drug, methimazole (MMZ) at 1.97 Šresolution. LPO was isolated from caprine colostrum, purified to homogeneity and crystallized with 20% poly(ethylene glycol)-3350. Crystals of LPO were soaked in a reservoir solution containing MMZ. The structure determination showed the presence of two crystallographically independent molecules in the asymmetric unit. Both molecules contained one molecule of MMZ, but with different

Full Text available with Trip Pro

2016 FEBS open bio

39. Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' Disease (PubMed)

Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' Disease Finding agranulocytosis (AG) at an early stage is important to improve outcome, but periodic granulocyte count monitoring is not generally recommended for patients with Graves' disease, because AG develops suddenly.At the Kuma Hospital, Graves' patients under antithyroid drug (ATD) treatment in an outpatient clinic have a granulocyte count

Full Text available with Trip Pro

2016 European thyroid journal

40. Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling. (PubMed)

' disease and Hashimoto's thyroiditis.Sixty-six patients (58 females:8 males) comprising 53 with Graves' disease and 13 with Hashimoto's thyroiditis were diagnosed at median 10.4 (2.9-15.8) years and followed up for 11.8 (2.6-30.2) years. Antithyroid drug (ATD) therapy was stopped electively in 35 patients after 4.5 (1.5-8.6) years, resulting in remission in 10/13 Hashimoto's thyroiditis and 10/22 Graves' disease. Side effects occurred in 12 patients receiving carbimazole, six of whom changed (...) Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling. Thyrotoxicosis is both rarer and more severe in children than in adults, rendering management difficult and often unsatisfactory.To ascertain outcome in a geographically defined area of Scotland between 1989 and 2014.Retrospective case note review with follow-up questionnaire to family doctors for patients with Graves

Full Text available with Trip Pro

2017 Archives of Disease in Childhood

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>